Skip to main content

Myasthenia gravis with achalasia secondary to thymoma: a case report and literature review



Myasthenia gravis is an autoimmune neuromuscular junction disorder characterized by fatigable muscle weakness and autoantibodies. Frequent associations exist between myasthenia gravis and thymic abnormalities, including hyperplasia and thymoma. Several autoimmune illnesses have been identified to be associated with thymoma; however, a few case reports have linked thymoma and achalasia, and the underlying mechanism is unknown.

Case report

A 43-year-old man with thymoma-associated myasthenia gravis presented with dysphagia that was refractory to conventional treatment of myasthenia gravis. This dysphagia was challenging to diagnose even after multiple gastroenterology consults and upper endoscopy. The diagnosis of achalasia type II was established after a comprehensive evaluation, including upper endoscopy, barium swallow, and high-resolution esophageal manometry. The patient underwent elective pneumatic balloon dilatation, which successfully alleviated his dysphagia.


This case confirmed the association between myasthenia gravis secondary to thymoma and achalasia and showed how the diagnosis of achalasia was challenging. Awareness of this association is crucial for early diagnosis and treatment, improving affected patients’ quality of life.


Myasthenia gravis (MG) is an autoimmune neuromuscular junction disorder characterized by fatigable muscle weakness and the presence of autoantibodies, with acetylcholine receptor (AChR) antibodies presented in up to 80% of individuals with generalized MG [1]. MG commonly includes the extraocular muscles, causing diplopia and/or ptosis. Generalized MG affects the face, axial, limb, bulbar, and respiratory muscles. MG is often linked with thymic abnormalities, including hyperplasia and thymoma; thymus imaging is suggested at presentation [2].

Thymomas, the most prevalent primary anterior mediastinal mass, are rare primary mediastinal tumors arising from the thymic epithelium [3]. Approximately one-third of thymoma cases are identified during a radiographic assessment for an autoimmune disease, most commonly MG [4]. Other autoimmune diseases linked to thymoma and discovered during or after thymectomy included systemic lupus erythematosus, inflammatory myopathies, thyroid abnormalities, and others [5, 6]. Achalasia was detected among these autoimmune conditions [7]. Achalasia is a rare esophageal motility condition characterized by abnormalities in the esophageal body’s motility and the relaxation of the lower esophageal sphincter (LES) [8, 9]. Achalasia, which can cause severe dysphagia, substantially impacts patients’ quality of life (QoL) and can be challenging to detect and treat [10].

In humans, the coexistence of MG with achalasia or megaesophagus has been established infrequently [11]; nevertheless, this coexistence is common in animals such as dogs, cats, and rodents [11, 12]. A few case reports described the association between MG and achalasia [13,14,15] and the association of thymoma with paraneoplastic MG and achalasia [16, 17]. Herein, we describe the first Egyptian case report that suffered from MG secondary to thymoma and associated with dysphagia with food regurgitation due to achalasia.

Case presentation

A 43-year-old male patient, a cigarette smoker who works as an office employee, was diagnosed with MG in February 2019. The condition started on December 2018 with weakness in the left side of his face associated with dysarthria that was misdiagnosed as left Bell’s palsy, for which the patient received steroid therapy and physiotherapy with no response to the medication. A few months later, the condition progressed to be associated with diplopia with a blurring of vision, followed by bulbar manifestations in the form of dysphagia with nasal regurgitation to fluid and frequent choking. Within a few days, the patient developed neck muscle weakness, especially flexion, with proximal weakness of the upper and lower limbs. These manifestations had diurnal variation, with increased symptoms at the end of the day and increased with exertion. Till this time, the patient received non-specific treatment.

The patient sought medical advice, and repetitive nerve stimulation in the frontalis and deltoid muscles was done in February 2019, revealing a positive decrement test for myasthenia. The serum level of the acetylcholine antibody was positive, and the titer was 7.9 nmol/l (negative if < 0.4 nmol/l). The patient was hospitalized and received six sessions of plasmapheresis with complete improvement. During this time, no chest imaging was done to assess the thymus gland status and the patient was managed conservatively and was prescribed acetylcholine esterase inhibitors (pyridostigmine 60 mg) twice daily with azathioprine twice daily and steroids that were gradually tapered, but the patient was incompliant with the treatment and developed recurrent attacks of exacerbations.

In September 2021, the patient complained of epigastric pain, dysphagia, and repeated food regurgitation and sought medical advice several times. Upper endoscopy revealed only hyperemic edematous mucosa with multiple fundal and pre-pyloric gastric ulcers. The patient was prescribed medical treatment with proton pump inhibitors with no improvement in his gastrointestinal tract (GIT) symptoms (vomiting and dysphagia, described as a sensation of food sticking behind his chest).

In November 2021, the patient developed worsening of his MG symptoms with a chest infection suggestive of pneumonia and was admitted to the hospital’s intermediate care unit. The patient was investigated for Corona Virus Disease 2019 (COVID-19) infection with a complete metabolic profile, and multislice computed tomography (MSCT) chest were done. The complete metabolic profile was normal, apart from absolute lymphopenia. The MSCT chest with and without contrast showed a ground glass appearance in both lungs suggestive of COVID-19 (CORAD III). Other findings in the MSCT chest included: iso-dense left anterior mediastinal soft tissue mass measuring about 6.7 × 6.7 × 5 cm, with minute foci of calcification. The mass showed homogenous enhancement in the post-contrast study, partially encasing the left innominate vein with no definite infiltration (Fig. 1a). Also, the distal part of the esophagus was minimally dilated and filled with fluid with no definite mass lesion. At first, the patient was managed for his COVID-19 infection. In January 2022, after controlling the infection, CT guided true cut needle biopsy (Fig. 1b) was done for his left anterior mediastinal mass, which revealed undifferentiated neoplasm for immunohistochemistry.

Fig. 1
figure 1

a Red arrow in the axial view of the chest’s computed tomography showing thymoma. b True cut needle biopsy

A few days later, the patient was transferred to neurology due to his myasthenic crisis. His neurological examination showed bilateral ptosis, diplopia, weakness of muscle of facial expression, neck muscle weakness more in neck flexors, and proximal weakness of both upper and lower limbs (grade 4a according to the medical research council muscle grading system), with unremarkable rest of neurological examination. The patient received five sessions of plasmapheresis with complete improvement apart from unexplained persistent dysphagia and vomiting. The patient was assessed by a cardiothoracic consultant and prepared for elective thymectomy. In March 2022, transsternal extending thymectomy of left thymus mass with partial resection of innominate vein via median sternotomy. The histopathological examination revealed a picture of thymoma type B2, p T1 (cortical thymoma and polygonal cell thymoma). After surgery, the patient was stable because he did not need postoperative mechanical ventilation and did not develop a postoperative myasthenic crisis. The patient was discharged home and received the postoperative treatment (levofloxacin, bronchodilators and anti-inflammatory) and continued MG medication (pyridostigmine 60 mg four times daily).

In June 2022, another attack of MG exacerbation for which the patient was admitted and received five sessions of plasmapheresis with partial improvement of his symptoms except for persistent vomiting after meals and regurgitation of undigested food with dysphagia. The patient was discharged on medical treatment (pyridostigmine 60 mg three times daily, azathioprine 50 mg twice daily, and steroid with gradual tapering). After gastroenterology consultation for his GIT symptoms and investigations, including upper endoscopy, barium swallow, and high-resolution esophageal manometry (HRM), the diagnosis of achalasia was confirmed. Upper endoscopy showed dilated esophagus with retained fluid and spastic cardia (Fig. 2a, b). The barium swallow study showed dilated esophagus with a bird beak appearance, and HRM showed achalasia type II (Fig. 2c). In July 2022, elective pneumatic balloon dilatation (PBD) (Fig. 3a, b) was done with successful dilation and remarkable improvement of the patient’s GIT symptoms. The patient is now stable on his MG medical treatment for the sixth month’s follow-up.

Fig. 2
figure 2

a Upper gastrointestinal endoscopy showing dilated esophagus and retained fluids. b Tight lower esophageal sphincter. c HRM of achalasia type II: showed the failure of LES relaxation, high resting LES pressure, and absent esophageal peristalsis (100%) with panesophageal pressurization to greater than 30 mmHg

Fig. 3
figure 3

Fluoroscopic image of achalasia using a 3.5-cm pneumatic dilator showing: a pneumatic balloon dilation with subsequent dilation to obliterate the balloon waist; b after successful pneumatic balloon dilation with balloon inflation to the maximum pressure of 13 mmHg


A 43-year-old male patient with MG and thymectomy complained of persistent vomiting and dysphagia after swallowing each meal that did not respond to standard MG therapy, including thymectomy and rapid immunomodulatory therapy (plasmapheresis). These GIT symptoms necessitated gastroenterology consultations several times that finally succeeded in adequately diagnosing the associated condition, achalasia type II, and prescribed the proper therapy, including pneumatic balloon dilatation with a complete improvement of the patient’s symptoms.

The current case report demonstrates the association of thymoma with MG and achalasia. This case replicates the previous finding reported by other studies [16, 17] that described two cases with a similar association of the three conditions with different ages of presentation. In other case reports, thymoma was associated with neuromuscular conditions, such as megaesophagus, without any neurological evidence of MG [7]. Moreover, MG was reported to be associated with megaesophagus without thymoma [11] or MG with achalasia without thymoma [13,14,15]. Furthermore, achalasia could be a complication of radiotherapy for thymoma that cause MG [18]. The cases of MG with achalasia with and without thymoma [11, 13,14,15,16,17] are summarized in Table 1.

Table 1 A literature review of case reports with MG and achalasia with and without thymoma

The current case had two important practical issues that required explanation; the first was the exacerbation of myasthenic symptoms 2.5 months after thymectomy despite the initial improvement, and the second was the delay in detecting the achalasia associated with MG related to thymoma.

Regarding the first issue, the response to thymectomy is variable, with some patients experiencing worsening and recurrence of MG symptoms or myasthenic crisis (MC) following thymectomy. Up to 50% of MG patients undergoing thymectomy, with an average follow-up duration of 7.0–8.9 years, have a relapse after achieving initial clinical responses [19]. This relapse of MG was identified to be related to several risk factors reported in earlier research [19,20,21,22]. Patients with thymoma were more likely to have a recurrence of their myasthenic symptoms after they reached complete stable remission and within a shorter period than in patients without thymoma [20], and this is more seen with type B2–B3 thymomas than those with A-B1 types according to the WHO histologic classification [21]. This could be explained by the fact that thymoma extrusion is inevitable during thymectomy, and auto-reactive T cells may be released from the thymoma into the peripheral circulation, resulting in autoimmunity and deterioration of MG status [23]. Other risk factors, including bulbar symptoms, generalized MG, and a history of previous MC, were identified as independent predictors of MG relapse after thymectomy [23]. The use of medications that are contraindicated in patients with MG, such as fluoroquinolones, can also exacerbate MG symptoms [24, 25].

All of these risk factors were present in the current patient, who had a history of thymoma type B2, GIT symptoms due to achalasia that could lead to infection, which is a trigger for developing relapse, a history of several exacerbations of his myasthenic symptoms, and postoperative treatment with levofloxacin (fluoroquinolone antibiotics).

Regarding the second issue, in the current case, the patient has complained of persistent dysphagia from September 2021 to June 2022, which means more than one and a half years to reach an accurate diagnosis. The patient was misdiagnosed as having pre-pyloric gastric ulcers as a cause for his vomiting. In this case, the delay in diagnosing achalasia could be explained by his MG, which is associated with dysphagia as bulbar muscle involvement, which could result in the regurgitation of food and fluid. Also, gastric ulcers could be related to the steroid therapy the patient received during his MG crisis. Accurate assessment of such cases is essential to avoid delay in diagnosis, which impacts the patient’s QoL and provide the appropriate intervention and treatment to improve the patient’s QoL.

Since achalasia still represents a challenging area for diagnosis and treatment in current practice [8], especially with non-professional gastroenterologists, accurate diagnosis requires a methodical diagnostic procedure. The diagnostic gold standard for achalasia is high-resolution esophageal manometry, which allows subtype definition and differentiation from other esophageal motor diseases [8, 26, 27]. The exact mechanism of achalasia is unknown [28, 29]; however, it was suggested that an autoimmune reaction targets esophageal myenteric neurons through cell-mediated and potential antibody-mediated processes in genetically predisposed patients is the potential mechanism of achalasia [9]. Moreover, it has been postulated that achalasia is not caused by a single mechanism but rather by a combination of infectious, autoimmune, and familial etiological factors. Recent evidence suggests that muscular eosinophilic esophagitis may have a role in the pathogenesis of achalasia in some patients [30].

The explanation of the association between thymoma and achalasia still needs to be determined. Some mechanisms have been proposed; Old report by Demos and colleagues proposed a hormonal relationship to be the cause of both illnesses, and the rationale for their assumption is the previous findings by Hasner and colleagues [31], who found that achalasia is more with benign thymoma, so achalasia in patients with thymoma is not limited to esophageal compression. Therefore, there may be more than a mechanical explanation for dysphagia in thymoma patients [7].

Another proposed mechanism is that the eosinophils may explain the connection between thymoma and achalasia caused by eosinophilic esophagitis. Eosinophils are innate immune system cells that primarily dwell within tissues and are most abundant in the GIT, excluding the healthy esophagus [32, 33]. Eosinophils only invade the esophagus during eosinophilic esophagitis, although their role is uncertain. In addition, eosinophils are also present in the human thymus, although their role in T cell development is unknown [32, 33]. T cell suppression is proposed as a potential function of eosinophils in eosinophilic esophagitis, and thymic eosinophils are demonstrated to be specialized cells capable of influencing thymocyte growth [33]. However, this mechanism needs confirmation by histopathological testing for the achalasia associated with thymoma. Depending on these assumptions, a common autoimmune mechanism, which still needs to be detected, could explain the association between the three conditions.

In conclusion, the current case confirmed the association between myasthenia gravis secondary to thymoma and achalasia. In addition, it has raised neurologists’ knowledge and awareness of achalasia in patients of MG complaining of recurrent vomiting and dysphagia resistant to standard therapy, which includes thymectomy and rapid immunomodulatory therapy. In addition, gastroenterologists, who may encounter a patient with MG who complains of dysphagia and is referred for an upper endoscopy, should consider this alternative diagnosis when examining and investigating the patient’s dysphagia.

Availability of data and materials

Not applicable.



Acetylcholine receptor


Corona Virus Disease 2019


Gastrointestinal tract


High-resolution esophageal manometry


Multislice computed tomography


Myasthenia gravis


Myasthenic crisis


Quality of life


  1. Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren JJGM. Myasthenia gravis. Nat Rev Dis Primers. 2019;5(1):30.

    Article  PubMed  Google Scholar 

  2. Damato V, Viegas S, Vincent A. Chapter 53—myasthenia gravis and related disorders. In: Rose NR, Mackay IR, editors. The Autoimmune Diseases (Sixth Edition). Academic Press; 2020. p. 1011–33.

    Chapter  Google Scholar 

  3. Scorsetti M, Leo F, Trama A, D’Angelillo R, Serpico D, Macerelli M, et al. Thymoma and thymic carcinomas. Crit Rev Oncol Hematol. 2016;99:332–50.

    Article  PubMed  Google Scholar 

  4. Detterbeck FC, Parsons AM. Thymic tumors. Ann Thorac Surg. 2004;77(5):1860–9.

    Article  PubMed  Google Scholar 

  5. Jamilloux Y, Frih H, Bernard C, Broussolle C, Petiot P, Girard N, et al. Thymoma and autoimmune diseases. Rev Med Interne. 2018;39(1):17–26.

    Article  CAS  PubMed  Google Scholar 

  6. Shelly S, Agmon-Levin N, Altman A, Shoenfeld Y. Thymoma and autoimmunity. Cell Mol Immunol. 2011;8(3):199–202.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Demos NJ, Yadusky RJ, Timmes JJ, Poulos PP. Thymoma associated with megaesophagus. J Thorac Cardiovasc Surg. 1966;51(5):708–13.

    Article  CAS  PubMed  Google Scholar 

  8. Ribolsi M, Andrisani G, Di Matteo FM, Cicala M. Achalasia, from diagnosis to treatment. Expert Rev Gastroenterol Hepatol. 2023;17(1):21–30.

    Article  CAS  PubMed  Google Scholar 

  9. Savarino E, Bhatia S, Roman S, Sifrim D, Tack J, Thompson SK, et al. Achalasia. Nat Rev Dis Primers. 2022;8(1):28.

    Article  PubMed  Google Scholar 

  10. Pandolfino JE, Gawron AJ. Achalasia: a systematic review. JAMA. 2015;313(18):1841–52.

    Article  PubMed  Google Scholar 

  11. Desuter G, Van Parijs V, Gardiner Q. Megaesophagus associated with myasthenia gravis: a rare condition in humans. B-ENT. 2015;11(1):63–6.

    CAS  PubMed  Google Scholar 

  12. Kempf J, Beckmann K, Kook PH. Achalasia-like disease with esophageal pressurization in a myasthenic dog. J Vet Intern Med. 2014;28(2):661–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Kornizky Y, Heller I, Isakov A, Shapira I, Topilsky M. Dysphagia with multiple autoimmune disease. Clin Rheumatol. 2000;19(4):321–3.

    Article  CAS  PubMed  Google Scholar 

  14. Rison RA. Reversible oropharyngeal dysphagia secondary to cricopharyngeal sphincter achalasia in a patient with myasthenia gravis: a case report. Cases J. 2009;2(1):1–3.

    Article  Google Scholar 

  15. Vinod D. Autoimmunity strikes neuromuscular junction: myasthenia gravis & achalasia cardia. Indian J Med Res. 2020;152(Suppl 1):S146.

    PubMed  PubMed Central  Google Scholar 

  16. Kaminski HJ. Achalasia and myasthenia gravis in a patient with thymoma. Neurology. 1999;52(2):425.

    Article  CAS  PubMed  Google Scholar 

  17. Seabi M, Mokgoko D. A case of achalasia and thymoma-associated myasthenia gravis. South Afr Gastroenterol Rev. 2020;18(3):18–9.

    Google Scholar 

  18. Prieto JL, Soria MJ, Peña JA, Infantes JM, Navas CJ, Martín L. Achalasia secondary to radiotherapy in a patient with thymoma and myasthenia gravis. Rev Esp Enferm Dig. 2001;93(2):125–6.

    CAS  PubMed  Google Scholar 

  19. Chen K, Li Y, Yang H. Poor responses and adverse outcomes of myasthenia gravis after thymectomy: predicting factors and immunological implications. J Autoimmun. 2022;132:102895.

    Article  PubMed  Google Scholar 

  20. Hsu H-S, Huang C-S, Huang B-S, Lee H-C, Kao K-P, Hsu W-H, et al. Thymoma is associated with relapse of symptoms after transsternal thymectomy for myasthenia gravis. Interact Cardiovasc Thorac Surg. 2006;5(1):42–6.

    Article  PubMed  Google Scholar 

  21. Xue L, Wang L, Dong J, Yuan Y, Fan H, Zhang Y, et al. Risk factors of myasthenic crisis after thymectomy for thymoma patients with myasthenia gravis†. Eur J Cardiothorac Surg. 2017;52(4):692–7.

    Article  PubMed  Google Scholar 

  22. Farrugia ME, Goodfellow JA. A practical approach to managing patients with myasthenia gravis—opinions and a review of the literature. Front Neurol. 2020.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Geng Y, Zhang H, Wang Y. Risk factors of myasthenia crisis after thymectomy among myasthenia gravis patients: a meta-analysis. Medicine. 2020;99(1):e18622.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Trillenberg P, Thern J. Antibiotic-induced myasthenia worsening—an estimation of risk based on reporting frequency. J Antimicrob Chemother. 2020;75(11):3408–10.

    Article  CAS  PubMed  Google Scholar 

  25. Jones SC, Sorbello A, Boucher RM. Fluoroquinolone-associated myasthenia gravis exacerbation: evaluation of postmarketing reports from the US FDA adverse event reporting system and a literature review. Drug Saf. 2011;34(10):839–47.

    Article  CAS  PubMed  Google Scholar 

  26. Stavropoulos SN, Friedel D, Modayil R, Parkman HP. Diagnosis and management of esophageal achalasia. BMJ. 2016;354:i2785.

    Article  PubMed  Google Scholar 

  27. Mari A, Patel K, Mahamid M, Khoury T, Pesce M. Achalasia: insights into diagnostic and therapeutic advances for an ancient disease. Rambam Maimonides Med J. 2019.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Storch WB, Eckardt VF, Wienbeck M, Eberl T, Auer PG, Hecker A, et al. Autoantibodies to Auerbach’s plexus in achalasia. Cell Mol Biol. 1995;41(8):1033–8.

    CAS  PubMed  Google Scholar 

  29. Patel DA, Lappas BM, Vaezi MF. An overview of achalasia and its subtypes. Gastroenterol Hepatol (N Y). 2017;13(7):411–21.

    PubMed  Google Scholar 

  30. Rieder E, Fernandez-Becker NQ, Sarosiek J, Guillaume A, Azagury DE, Clarke JO. Achalasia: physiology and diagnosis. Ann N Y Acad Sci. 2020;1482(1):85–94.

    Article  PubMed  Google Scholar 

  31. Hasner E. Thymomas. Acta Chir Scand. 1963;126:58–65.

    CAS  PubMed  Google Scholar 

  32. Ferguson DD, Foxx-Orenstein AE. Eosinophilic esophagitis: an update. Dis Esophagus. 2007;20(1):2–8.

    Article  CAS  PubMed  Google Scholar 

  33. Albinsson Högberg S. A study of eosinophils–from the human thymus to eosinophilic esophagitis [Doctoral thesis]: University of Gothenburg; 2022.

Download references


The authors thank the patient and his family for cooperating in this study.


The authors declare no sources of funding.

Author information

Authors and Affiliations



NH contributed to the writing of the original draft of the case report. NH, EK, and AM collaborated on the manuscript’s data collection, follow-up, and critical review. AM, EA, and AA collaborated on the GIT intervention and contributed to the critical review of this manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Nourelhoda A. Haridy.

Ethics declarations

Ethics approval and consent to participate

Case reports are exempt from IRB approval in our institution, which is why no IRB approval was taken. We confirm that the manuscript reporting adheres to CARE guidelines.

Consent for publication

A written informed consent was obtained from the patient to publish this case report. The case report does not include identifiable data.

Competing interests

The authors declare no conflicts of interest associated with this manuscript.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Haridy, N.A., Khedr, E.M., Hasan, A.M. et al. Myasthenia gravis with achalasia secondary to thymoma: a case report and literature review. Egypt J Neurol Psychiatry Neurosurg 59, 34 (2023).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: